Advanced microbiome therapeutics as a novel modality for oral delivery of peptides to manage metabolic diseases

87

Advanced microbiome therapeutics as a novel modality for oral delivery of peptides to manage metabolic diseases

Tags:

Previous Article

Parkinson’s disease pathogenesis from G6PD deficiency

Treating metabolic diseases with microbes containing peptides

Related Posts

Alzheimer’s genetic risk factor Bin1 controls synapse vesicle exo-endocytosis in inhibitory synapses

Alzheimer’s genetic risk factor Bin1 controls synapse v...

99

Alpha-synuclein misfolding as fluid biomarker for Parkinson’s disease measured with the iRS platform

Alpha-synuclein misfolding as fluid biomarker for Parki...

106

ARMC5 selectively degrades SCAP-free SREBF1 and is essential for fatty acid desaturation in adipocytes

ARMC5 selectively degrades SCAP-free SREBF1 and is esse...

99